The US FDA has found “credible evidence” of medicinal benefits in cannabis, potentially leading to its reclassification from schedule one to schedule three. The review also highlighted low physical dependence risk in young people. President Biden’s order prompted the review, and support for reclassification comes from organisations like the National Institute on Drug Abuse and the US Department of Health Services.
Read the original story here (opens in new tab)
Source: Cannabiz (opens in new tab)